FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2916187475> ?p ?o ?g. }

• W2916187475 endingPage "369" @default.
• W2916187475 startingPage "361" @default.
• W2916187475 abstract "To review the latest evidence on the oncologic urology of prostate, renal and bladder tumors, analysing their impact on daily clinical practice and future medium to long-term regimens. We review the abstracts on prostate, renal and bladder cancer presented at the 2015 congresses (EAU, AUA, ASCO, ESMO and ASTRO) that received the best evaluations by the OncoForum committee. Cabozantinib could represent a new second-line (or subsequent) treatment option for patients with advanced renal cancer. In muscle-invasive bladder cancer, the genetic expression profile could predict the clinical benefit of neoadjuvant therapy in treating urothelial tumors. In metastatic castration-resistant prostate cancer, results were presented from various studies that evaluated the addition of chemotherapy to standard treatment with androgen deprivation, showing a reduction in the progression risk and higher PSA response rates. New options for the second-line treatment of renal cancer were presented. In metastatic castration-resistant prostate cancer, various studies have been published on treatment with enzalutamide, which has been shown to delay the symptomatic disease and benefit overall survival. Conocer las últimas evidencias sobre urología oncológica de tumores de próstata, riñón y vejiga, analizando su impacto en la práctica clínica diaria, además de los esquemas futuros a medio y largo plazo. Se revisan los resúmenes sobre cáncer de próstata, renal y de vejiga presentados en los congresos del año 2015 (EAU, AUA, ASCO, ESMO y ASTRO) que recibieron mayor valoración por parte del comité de OncoForum. En pacientes con cáncer renal avanzado, cabozantinib podría representar una nueva opción de tratamiento en segunda línea o posteriores. En cáncer de vejiga musculoinvasivo, el perfil de expresión genética podría predecir el beneficio clínico de la neoadyuvancia en el tratamiento de tumores uroteliales. En cáncer de próstata resistente a castración metastásico se han presentado resultados de diferentes estudios que han evaluado la adición de quimioterapia al tratamiento estándar con privación androgénica, mostrando reducción del riesgo de la progresión y tasas de respuesta de PSA más elevadas. En cáncer renal se han presentado nuevas opciones en segunda línea de tratamiento. En cáncer de próstata resistente a castración metastásico se han publicado diferentes estudios sobre el tratamiento con enzalutamida en los que se ha mostrado que puede retrasar la enfermedad sintomática y tener un beneficio sobre la supervivencia global." @default.
• W2916187475 created "2019-03-02" @default.
• W2916187475 creator A5006442843 @default.
• W2916187475 creator A5007357362 @default.
• W2916187475 creator A5044441718 @default.
• W2916187475 creator A5061698332 @default.
• W2916187475 date "2016-07-01" @default.
• W2916187475 modified "2023-10-18" @default.
• W2916187475 title "Developments in urologic oncology “OncoForum”: The best of 2015" @default.
• W2916187475 cites W1754265771 @default.
• W2916187475 cites W1856370515 @default.
• W2916187475 cites W1931245198 @default.
• W2916187475 cites W1946476244 @default.
• W2916187475 cites W1968554767 @default.
• W2916187475 cites W1969825763 @default.
• W2916187475 cites W1980762548 @default.
• W2916187475 cites W1981174503 @default.
• W2916187475 cites W1989975543 @default.
• W2916187475 cites W2023373206 @default.
• W2916187475 cites W2029951927 @default.
• W2916187475 cites W2034119386 @default.
• W2916187475 cites W2041957175 @default.
• W2916187475 cites W2047532445 @default.
• W2916187475 cites W2058833787 @default.
• W2916187475 cites W2064425060 @default.
• W2916187475 cites W2064437042 @default.
• W2916187475 cites W2074855084 @default.
• W2916187475 cites W2113873671 @default.
• W2916187475 cites W2166918329 @default.
• W2916187475 cites W2178183066 @default.
• W2916187475 cites W2214621962 @default.
• W2916187475 cites W2216819529 @default.
• W2916187475 cites W2222086386 @default.
• W2916187475 cites W2237254160 @default.
• W2916187475 cites W2287073069 @default.
• W2916187475 cites W2317696827 @default.
• W2916187475 cites W2326987552 @default.
• W2916187475 cites W2333332433 @default.
• W2916187475 cites W2346791303 @default.
• W2916187475 cites W2463252837 @default.
• W2916187475 cites W2466133895 @default.
• W2916187475 cites W2509852248 @default.
• W2916187475 cites W2512470145 @default.
• W2916187475 cites W2523547317 @default.
• W2916187475 cites W2583161699 @default.
• W2916187475 cites W2590934127 @default.
• W2916187475 cites W2599411470 @default.
• W2916187475 cites W2615367410 @default.
• W2916187475 cites W2916742936 @default.
• W2916187475 cites W3021351480 @default.
• W2916187475 cites W3086795553 @default.
• W2916187475 doi "https://doi.org/10.1016/j.acuroe.2016.05.003" @default.
• W2916187475 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27061663" @default.
• W2916187475 hasPublicationYear "2016" @default.
• W2916187475 type Work @default.
• W2916187475 sameAs 2916187475 @default.
• W2916187475 citedByCount "4" @default.
• W2916187475 countsByYear W29161874752017 @default.
• W2916187475 countsByYear W29161874752018 @default.
• W2916187475 crossrefType "journal-article" @default.
• W2916187475 hasAuthorship W2916187475A5006442843 @default.
• W2916187475 hasAuthorship W2916187475A5007357362 @default.
• W2916187475 hasAuthorship W2916187475A5044441718 @default.
• W2916187475 hasAuthorship W2916187475A5061698332 @default.
• W2916187475 hasConcept C121608353 @default.
• W2916187475 hasConcept C126322002 @default.
• W2916187475 hasConcept C126894567 @default.
• W2916187475 hasConcept C143998085 @default.
• W2916187475 hasConcept C2776551883 @default.
• W2916187475 hasConcept C2777899217 @default.
• W2916187475 hasConcept C2780192828 @default.
• W2916187475 hasConcept C2780352672 @default.
• W2916187475 hasConcept C2781064419 @default.
• W2916187475 hasConcept C29456083 @default.
• W2916187475 hasConcept C61367390 @default.
• W2916187475 hasConcept C71924100 @default.
• W2916187475 hasConceptScore W2916187475C121608353 @default.
• W2916187475 hasConceptScore W2916187475C126322002 @default.
• W2916187475 hasConceptScore W2916187475C126894567 @default.
• W2916187475 hasConceptScore W2916187475C143998085 @default.
• W2916187475 hasConceptScore W2916187475C2776551883 @default.
• W2916187475 hasConceptScore W2916187475C2777899217 @default.
• W2916187475 hasConceptScore W2916187475C2780192828 @default.
• W2916187475 hasConceptScore W2916187475C2780352672 @default.
• W2916187475 hasConceptScore W2916187475C2781064419 @default.
• W2916187475 hasConceptScore W2916187475C29456083 @default.
• W2916187475 hasConceptScore W2916187475C61367390 @default.
• W2916187475 hasConceptScore W2916187475C71924100 @default.
• W2916187475 hasIssue "6" @default.
• W2916187475 hasLocation W29161874751 @default.
• W2916187475 hasOpenAccess W2916187475 @default.
• W2916187475 hasPrimaryLocation W29161874751 @default.
• W2916187475 hasRelatedWork W2021751111 @default.
• W2916187475 hasRelatedWork W2309274182 @default.
• W2916187475 hasRelatedWork W2768688864 @default.
• W2916187475 hasRelatedWork W2776594178 @default.
• W2916187475 hasRelatedWork W3014214351 @default.
• W2916187475 hasRelatedWork W3023947295 @default.

• next